Secukinumab B
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
IL Receptor
CAS Number
1229022-83-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1358358-01 0.02 mg (E-Coli)
Recombinant Streptococcus pneumoniae Serine--tRNA ligase (serS)
Ask
View Details 
MBS1358358-02 0.02 mg (Yeast)
Recombinant Streptococcus pneumoniae Serine--tRNA ligase (serS)
Ask
View Details 
MBS1358358-03 0.1 mg (E-Coli)
Recombinant Streptococcus pneumoniae Serine--tRNA ligase (serS)
Ask
View Details MBS1358358-04 0.1 mg (Yeast)
Recombinant Streptococcus pneumoniae Serine--tRNA ligase (serS)
Ask
View Details MBS1358358-05 0.02 mg (Baculovirus)
Recombinant Streptococcus pneumoniae Serine--tRNA ligase (serS)
Ask
View Details MBS1358358-06 0.02 mg (Mammalian-Cell)
Recombinant Streptococcus pneumoniae Serine--tRNA ligase (serS)
Ask
View Details